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Abstract 
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed 
to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past 
decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 
statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, 
and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we 
present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 
2020 abstract checklist, and the revised flow diagrams for original and updated reviews. © 2021 Published by Elsevier Inc. 
Keywords: Systematic review; Meta-analysis; Reporting guideline; Transparency; Reproducibility; Checklist 
1. Introduction 
Systematic reviews serve many critical roles. They can 
provide syntheses of the state of knowledge in a field, from 
which future research priorities can be identified; they can 
address questions that otherwise could not be answered by 
individual studies; they can identify problems in primary 
research that should be rectified in future studies; and they 
can generate or evaluate theories about how or why phe- 
nomena occur. Systematic reviews therefore generate vari- 
ous types of knowledge for different users of reviews (such 
as patients, healthcare providers, researchers, and policy 
makers) [1 , 2] . To ensure a systematic review is valuable 
to users, authors should prepare a transparent, complete, 
and accurate account of why the review was done, what 
they did (such as how studies were identified and selected) 
and what they found (such as characteristics of contributing 
studies and results of meta-analyses). Up-to-date reporting 
guidance facilitates authors achieving this [3] . 
The Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) statement published in 2009 
(hereafter referred to as PRISMA 2009) [4–10] is a report- 
ing guideline designed to address poor reporting of system- 
atic reviews [11] . The PRISMA 2009 statement comprised 
a checklist of 27 items recommended for reporting in sys- 
tematic reviews and an “explanation and elaboration” paper 
[12–16] providing additional reporting guidance for each 
item, along with exemplars of reporting. The recommenda- 
tions have been widely endorsed and adopted, as evidenced 
by its copublication in multiple journals, citation in over 
60 000 reports (Scopus, August 2020), endorsement from 
almost 200 journals and systematic review organizations, 
and adoption in various disciplines. Evidence from obser- 
vational studies suggests that use of the PRISMA 2009 
statement is associated with more complete reporting of 
systematic reviews [17–20] , although more could be done 
to improve adherence to the guideline [21] . 
Many innovations in the conduct of systematic reviews 
have occurred since publication of the PRISMA 2009 state- 
ment. For example, technological advances have enabled 
the use of natural language processing and machine learn- 
ing to identify relevant evidence [22–24] , methods have 
been proposed to synthesise and present findings when 
meta-analysis is not possible or appropriate [25–27] , and 
new methods have been developed to assess the risk of bias 
in results of included studies [28 , 29] . Evidence on sources 
of bias in systematic reviews has accrued, culminating in 
the development of new tools to appraise the conduct of 
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systematic reviews [30 , 31] . Terminology used to describe 
particular review processes has also evolved, as in the 
shift from assessing “quality” to assessing “certainty” in 
the body of evidence [32] . In addition, the publishing 
landscape has transformed, with multiple avenues now 
available for registering and disseminating systematic re- 
view protocols [33 , 34] , disseminating reports of systematic 
reviews, and sharing data and materials, such as preprint 
servers and publicly accessible repositories. To capture 
these advances in the reporting of systematic reviews 
necessitated an update to the PRISMA 2009 statement. 
Box Summary points 
• To ensure a systematic review is valuable to users, 
authors should prepare a transparent, complete, and 
accurate account of why the review was done, what 
they did, and what they found. 
• The PRISMA 2020 statement provides updated re- 
porting guidance for systematic reviews that reflects 
advances in methods to identify, select, appraise, 
and synthesise studies. 
• The PRISMA 2020 statement consists of a 27-item 
checklist, an expanded checklist that details report- 
ing recommendations for each item, the PRISMA 
2020 abstract checklist, and revised flow diagrams 
for original and updated reviews. 
• We anticipate that the PRISMA 2020 statement will 
benefit authors, editors, and peer reviewers of sys- 
tematic reviews, and different users of reviews, in- 
cluding guideline developers, policy makers, health- 
care providers, patients, and other stakeholders. 
2. Development of PRISMA 2020 
A complete description of the methods used to develop 
PRISMA 2020 is available elsewhere [35] . We identified 
PRISMA 2009 items that were often reported incompletely 
by examining the results of studies investigating the trans- 
parency of reporting of published reviews [17 , 21 , 36 , 37] . 
We identified possible modifications to the PRISMA 2009 
statement by reviewing 60 documents providing reporting 
guidance for systematic reviews (including reporting 
guidelines, handbooks, tools, and meta-research studies) 
[38] . These reviews of the literature were used to inform 
the content of a survey with suggested possible modifi- 
cations to the 27 items in PRISMA 2009 and possible 
additional items. Respondents were asked whether they 
believed we should keep each PRISMA 2009 item as is, 
modify it, or remove it, and whether we should add each 
additional item. Systematic review methodologists and 
journal editors were invited to complete the online survey 
(110 of 220 invited responded). We discussed proposed 
content and wording of the PRISMA 2020 statement, as 
informed by the review and survey results, at a 21-member, 
2-day, in-person meeting in September 2018 in Edinburgh, 
Scotland. Throughout 2019 and 2020, we circulated an 
initial draft and five revisions of the checklist and expla- 
nation and elaboration paper to coauthors for feedback. In 
April 2020, we invited 22 systematic reviewers who had 
expressed interest in providing feedback on the PRISMA 
2020 checklist to share their views (via an online survey) 
on the layout and terminology used in a preliminary 
version of the checklist. Feedback was received from 15 
individuals and considered by the first author, and any 
revisions deemed necessary were incorporated before the 
final version was approved and endorsed by all coauthors. 
3. The PRISMA 2020 statement 
3.1. Scope of the guideline 
The PRISMA 2020 statement has been designed pri- 
marily for systematic reviews of studies that evaluate 
the effects of health interventions, irrespective of the de- 
sign of the included studies. However, the checklist items 
are applicable to reports of systematic reviews evaluat- 
ing other interventions (such as social or educational in- 
terventions), and many items are applicable to system- 
atic reviews with objectives other than evaluating inter- 
ventions (such as evaluating an etiology, prevalence, or 
prognosis). PRISMA 2020 is intended for use in system- 
atic reviews that include synthesis (such as pairwise meta- 
analysis or other statistical synthesis methods) or do not 
include synthesis (for example, because only one eligible 
study is identified). The PRISMA 2020 items are rele- 
vant for mixed-methods systematic reviews (which include 
quantitative and qualitative studies), but reporting guide- 
lines addressing the presentation and synthesis of qual- 
itative data should also be consulted [39 , 40] . PRISMA 
2020 can be used for original systematic reviews, up- 
dated systematic reviews, or continually updated (“living”) 
systematic reviews. However, for updated and living sys- 
tematic reviews, there may be some additional consider- 
ations that need to be addressed. Where there is rele- 
vant content from other reporting guidelines, we reference 
these guidelines within the items in the explanation and 
elaboration paper [41] (such as PRISMA-Search [42] in 
items 6 and 7, Synthesis without meta-analysis (SWiM) 
reporting guideline [27] in item 13d). Box 1 includes 
a glossary of terms used throughout the PRISMA 2020 
statement. 
Box 1 Glossary of terms 
Systematic review —A review that uses explicit, sys- 
tematic methods to collate and synthesise findings of 
studies that address a clearly formulated question [43] 
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Statistical synthesis —The combination of quantita- 
tive results of two or more studies. This encompasses 
meta-analysis of effect estimates (described below) 
and other methods, such as combining P values, cal- 
culating the range and distribution of observed effects, 
and vote counting based on the direction of effect (see 
McKenzie and Brennan [25] for a description of each 
method) 
Meta-analysis of effect estimates — A statistical 
technique used to synthesise results when study effect 
estimates and their variances are available, yielding a 
quantitative summary of results [25] 
Outcome — An event or measurement collected for 
participants in a study (such as quality of life, mor- 
tality) 
Result — The combination of a point estimate 
(such as a mean difference, risk ratio, or propor- 
tion) and a measure of its precision (such as a confi- 
dence/credible interval) for a particular outcome 
Report — A document (paper or electronic) supply- 
ing information about a particular study. It could be 
a journal article, preprint, conference abstract, study 
register entry, clinical study report, dissertation, un- 
published manuscript, government report, or any other 
document providing relevant information 
Record — The title or abstract (or both) of a report 
indexed in a database or website (such as a title or 
abstract for an article indexed in Medline). Records 
that refer to the same report (such as the same journal 
article) are “duplicates”; however, records that refer to 
reports that are merely similar (such as a similar ab- 
stract submitted to two different conferences) should 
be considered unique. 
Study — An investigation, such as a clinical trial, 
that includes a defined group of participants and one 
or more interventions and outcomes. A “study” might 
have multiple reports. For example, reports could in- 
clude the protocol, statistical analysis plan, baseline 
characteristics, results for the primary outcome, re- 
sults for harms, results for secondary outcomes, and 
results for additional mediator and moderator analyses 
PRISMA 2020 is not intended to guide systematic 
review conduct, for which comprehensive resources are 
available [43-46] . However, familiarity with PRISMA 2020 
is useful when planning and conducting systematic reviews 
to ensure that all recommended information is captured. 
PRISMA 2020 should not be used to assess the conduct 
or methodological quality of systematic reviews; other 
tools exist for this purpose [30 , 31] . Furthermore, PRISMA 
2020 is not intended to inform the reporting of system- 
atic review protocols, for which a separate statement is 
available (PRISMA for Protocols (PRISMA-P) 2015 
statement [47 , 48] ). Finally, extensions to the PRISMA 
2009 statement have been developed to guide reporting of 
network meta-analyses [49] , meta-analyses of individual 
participant data [50] , systematic reviews of harms [51] , 
systematic reviews of diagnostic test accuracy studies 
[52] , and scoping reviews [53] ; for these types of reviews 
we recommend authors report their review in accordance 
with the recommendations in PRISMA 2020 along with 
the guidance specific to the extension. 
4. How to use PRISMA 2020 
The PRISMA 2020 statement (including the checklists, 
explanation and elaboration, and flow diagram) replaces 
the PRISMA 2009 statement, which should no longer be 
used. Box 2 summarizes noteworthy changes from the 
PRISMA 2009 statement. The PRISMA 2020 checklist in- 
cludes seven sections with 27 items, some of which include 
sub-items ( Table 1 ). A checklist for journal and conference 
abstracts for systematic reviews is included in PRISMA 
2020. This abstract checklist is an update of the 2013 
PRISMA for Abstracts statement [54] , reflecting new and 
modified content in PRISMA 2020 ( Table 2 ). A template 
PRISMA flow diagram is provided, which can be modified 
depending on whether the systematic review is original or 
updated ( Fig. 1 ). 
Box 2 Noteworthy changes to the PRISMA 
2009 statement 
• Inclusion of the abstract reporting checklist within 
PRISMA 2020 (see item #2 and Table 2 ). 
• Movement of the ‘Protocol and registration’ item 
from the start of the Methods section of the check- 
list to a new Other section, with addition of a sub- 
item recommending authors describe amendments 
to information provided at registration or in the pro- 
tocol (see item #24a-24c). 
• Modification of the ‘Search’ item to recommend au- 
thors present full search strategies for all databases, 
registers and websites searched, not just at least one 
database (see item #7). 
• Modification of the ‘Study selection’ item in the 
Methods section to emphasize the reporting of how 
many reviewers screened each record and each re- 
port retrieved, whether they worked independently, 
and if applicable, details of automation tools used 
in the process (see item #8). 
• Addition of a subitem to the ‘Data items’ item rec- 
ommending authors report how outcomes were de- 
fined, which results were sought, and methods for 
selecting a subset of results from included studies 
(see item #10a). 
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• Splitting of the ‘Synthesis of results’ item in the 
Methods section into six subitems recommend- 
ing authors describe: the processes used to decide 
which studies were eligible for each synthesis; any 
methods required to prepare the data for synthe- 
sis; any methods used to tabulate or visually dis- 
play results of individual studies and syntheses; any 
methods used to synthesise results; any methods 
used to explore possible causes of heterogeneity 
among study results (such as subgroup analysis, 
meta-regression); and any sensitivity analyses used 
to assess robustness of the synthesized results (see 
item #13a-13f). 
• Addition of a subitem to the ‘Study selection’ item 
in the Results section recommending authors cite 
studies that might appear to meet the inclusion cri- 
teria, but which were excluded, and explain why 
they were excluded (see item #16b). 
• Splitting of the ‘Synthesis of results’ item in the 
Results section into four subitems recommending 
authors: briefly summaries the characteristics and 
risk of bias among studies contributing to the syn- 
thesis; present results of all statistical syntheses 
conducted; present results of any investigations of 
possible causes of heterogeneity among study re- 
sults; and present results of any sensitivity analyses 
(see item #20a-20d). 
• Addition of new items recommending authors re- 
port methods for and results of an assessment of 
certainty (or confidence) in the body of evidence 
for an outcome (see items #15 and #22). 
• Addition of a new item recommending authors de- 
clare any competing interests (see item #26). 
• Addition of a new item recommending authors indi- 
cate whether data, analytic code and other materials 
used in the review are publicly available and if so, 
where they can be found (see item #27). 
We recommend authors refer to PRISMA 2020 early 
in the writing process, because prospective considera- 
tion of the items may help to ensure that all the items 
are addressed. To help keep track of which items have 
been reported, the PRISMA statement website ( http:// 
www.prisma-statement.org/) includes fillable templates of 
the checklists to download and complete (also available 
in the Appendix). We have also created a web appli- 
cation that allows users to complete the checklist via 
a user-friendly interface [58] (available at https://prisma. 
shinyapps.io/ checklist/ and adapted from the Transparency 
Checklist app [59] ). The completed checklist can be ex- 
ported to Word or PDF. Editable templates of the flow 
diagram can also be downloaded from the PRISMA state- 
ment website. 
We have prepared an updated explanation and elabora- 
tion paper, in which we explain why reporting of each item 
is recommended and present bullet points that detail the re- 
porting recommendations (which we refer to as elements) 
[41] . The bullet-point structure is new to PRISMA 2020 
and has been adopted to facilitate implementation of the 
guidance [60 , 61] . An expanded checklist, which comprises 
an abridged version of the elements presented in the ex- 
planation and elaboration paper, with references and some 
examples removed, is available in the Appendix. Consult- 
ing the explanation and elaboration paper is recommended 
if further clarity or information is required. 
Journals and publishers might impose word and section 
limits, and limits on the number of tables and figures al- 
lowed in the main report. In such cases, if the relevant 
information for some items already appears in a publicly 
accessible review protocol, referring to the protocol may 
suffice. Alternatively, placing detailed descriptions of the 
methods used or additional results (such as for less criti- 
cal outcomes) in supplementary files is recommended. Ide- 
ally, supplementary files should be deposited to a general- 
purpose or institutional open-access repository that pro- 
vides free and permanent access to the material (such as 
Open Science Framework, Dryad, figshare). A reference 
or link to the additional information should be included in 
the main report. Finally, although PRISMA 2020 provides 
a template for where information might be located, the 
suggested location should not be seen as prescriptive; the 
guiding principle is to ensure the information is reported. 
5. Discussion 
Use of PRISMA 2020 has the potential to benefit many 
stakeholders. Complete reporting allows readers to assess 
the appropriateness of the methods, and therefore the trust- 
worthiness of the findings. Presenting and summarizing 
characteristics of studies contributing to a synthesis allows 
healthcare providers and policy makers to evaluate the ap- 
plicability of the findings to their setting. Describing the 
certainty in the body of evidence for an outcome and the 
implications of findings should help policy makers, man- 
agers, and other decision makers formulate appropriate rec- 
ommendations for practice or policy. Complete reporting 
of all PRISMA 2020 items also facilitates replication and 
review updates, as well as inclusion of systematic reviews 
in overviews (of systematic reviews) and guidelines, so 
teams can leverage work that is already done and decrease 
research waste [36 , 62 , 63] . 
We updated the PRISMA 2009 statement by adapting 
the EQUATOR Network’s guidance for developing health 
research reporting guidelines [64] . We evaluated the 
reporting completeness of published systematic reviews 
[17 , 21 , 36 , 37] , reviewed the items included in other doc- 
uments providing guidance for systematic reviews [38] , 
surveyed systematic review methodologists and journal 
editors for their views on how to revise the original 
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Table 1. PRISMA 2020 item checklist 
Section and topic Item # Checklist item Location where 
item is reported 
Title 
Title 1 Identify the report as a systematic review. 
Abstract 
Abstract 2 See the PRISMA 2020 for Abstracts checklist ( Table 2 ). 
Introduction 
Rationale 3 Describe the rationale for the review in the context of existing knowledge. 
Objectives 4 Provide an explicit statement of the objective(s) or question(s) the review addresses. 
Methods 
Eligibility criteria 5 Specify the inclusion and exclusion criteria for the review and how studies were 
grouped for the syntheses. 
Information 
sources 
6 Specify all databases, registers, websites, organisations, reference lists and other 
sources searched or consulted to identify studies. Specify the date when each source 
was last searched or consulted. 
Search strategy 7 Present the full search strategies for all databases, registers and websites, including 
any filters and limits used. 
Selection 
process 
8 Specify the methods used to decide whether a study met the inclusion criteria of the 
review, including how many reviewers screened each record and each report retrieved, 
whether they worked independently, and if applicable, details of automation tools 
used in the process. 
Data collection 
process 
9 Specify the methods used to collect data from reports, including how many reviewers 
collected data from each report, whether they worked independently, any processes 
for obtaining or confirming data from study investigators, and if applicable, details of 
automation tools used in the process. 
Data items 10a List and define all outcomes for which data were sought. Specify whether all results 
that were compatible with each outcome domain in each study were sought (e.g. for 
all measures, time points, analyses), and if not, the methods used to decide which 
results to collect. 
10b List and define all other variables for which data were sought (e.g. participant and 
intervention characteristics, funding sources). Describe any assumptions made about 
any missing or unclear information. 
Study risk of 
bias assessment 
11 Specify the methods used to assess risk of bias in the included studies, including 
details of the tool(s) used, how many reviewers assessed each study and whether they 
worked independently, and if applicable, details of automation tools used in the 
process. 
Effect measures 12 Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used 
in the synthesis or presentation of results. 
Synthesis 
methods 
13a Describe the processes used to decide which studies were eligible for each synthesis 
(e.g., tabulating the study intervention characteristics and comparing against the 
planned groups for each synthesis (item #5)). 
13b Describe any methods required to prepare the data for presentation or synthesis, such 
as handling of missing summary statistics, or data conversions. 
13c Describe any methods used to tabulate or visually display results of individual studies 
and syntheses. 
13d Describe any methods used to synthesise results and provide a rationale for the 
choice(s). If meta-analysis was performed, describe the model(s), method(s) to 
identify the presence and extent of statistical heterogeneity, and software package(s) 
used. 
13e Describe any methods used to explore possible causes of heterogeneity among study 
results (e.g., subgroup analysis, metaregression). 




14 Describe any methods used to assess risk of bias due to missing results in a synthesis 
(arising from reporting biases). 
( continued on next page ) 
Please cite this article as: M.J. Page et al., The PRISMA 2020 statement: An updated guideline for reporting systematic reviews, Journal of Clinical 
Epidemiology, https:// doi.org/ 10.1016/ j.jclinepi.2021.03.001 
M.J. Page et al. / Journal of Clinical Epidemiology xxx (xxxx) xxx 7 
ARTICLE IN PRESS 
JID: JCE [mNS; March 17, 2021;19:26 ] 
Table 1 ( continued ) 
Section and topic Item # Checklist item Location where 
item is reported 
Certainty 
assessment 
15 Describe any methods used to assess certainty (or confidence) in the body of evidence 
for an outcome. 
Results 
Study selection 16a Describe the results of the search and selection process, from the number of records 
identified in the search to the number of studies included in the review, ideally using 
a flow diagram (see Fig. 1 ). 
16b Cite studies that might appear to meet the inclusion criteria, but which were 
excluded, and explain why they were excluded. 
Study 
characteristics 
17 Cite each included study and present its characteristics. 
Risk of bias in 
studies 




19 For all outcomes, present, for each study: (a) summary statistics for each group 
(where appropriate) and (b) an effect estimate and its precision (e.g., 
confidence/credible interval), ideally using structured tables or plots. 
Results of 
syntheses 
20a For each synthesis, briefly summarise the characteristics and risk of bias among 
contributing studies. 
20b Present results of all statistical syntheses conducted. If meta-analysis was done, 
present for each the summary estimate and its precision (e.g., confidence/credible 
interval) and measures of statistical heterogeneity. If comparing groups, describe the 
direction of the effect. 
20c Present results of all investigations of possible causes of heterogeneity among study 
results. 
20d Present results of all sensitivity analyses conducted to assess the robustness of the 
synthesised results. 
Reporting biases 21 Present assessments of risk of bias due to missing results (arising from reporting 
biases) for each synthesis assessed. 
Certainty of 
evidence 
22 Present assessments of certainty (or confidence) in the body of evidence for each 
outcome assessed. 
Discussion 
Discussion 23a Provide a general interpretation of the results in the context of other evidence. 
23b Discuss any limitations of the evidence included in the review. 
23c Discuss any limitations of the review processes used. 




24a Provide registration information for the review, including register name and 
registration number, or state that the review was not registered. 
24b Indicate where the review protocol can be accessed, or state that a protocol was not 
prepared. 
24c Describe and explain any amendments to information provided at registration or in the 
protocol. 
Support 25 Describe sources of financial or nonfinancial support for the review, and the role of the 
funders or sponsors in the review. 
Competing 
interests 
26 Declare any competing interests of review authors. 
Availability of 
data, code, and 
other materials 
27 Report which of the following are publicly available and where they can be found: 
template data collection forms; data extracted from included studies; data used for all 
analyses; analytic code; any other materials used in the review. 
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Table 2. PRISMA 2020 for Abstracts checklist ∗
Section and topic Item # Checklist item 
Title 
Title 1 Identify the report as a systematic review. 
Background 
Objectives 2 Provide an explicit statement of the main objective(s) or question(s) the review 
addresses. 
Methods 
Eligibility criteria 3 Specify the inclusion and exclusion criteria for the review. 
Information sources 4 Specify the information sources (e.g. databases, registers) used to identify studies 
and the date when each was last searched. 
Risk of bias 5 Specify the methods used to assess risk of bias in the included studies. 
Synthesis of results 6 Specify the methods used to present and synthesise results. 
Results 
Included studies 7 Give the total number of included studies and participants and summarise relevant 
characteristics of studies. 
Synthesis of results 8 Present results for main outcomes, preferably indicating the number of included 
studies and participants for each. If meta-analysis was done, report the summary 
estimate and confidence/credible interval. If comparing groups, indicate the direction 
of the effect (i.e. which group is favoured). 
Discussion 
Limitations of evidence 9 Provide a brief summary of the limitations of the evidence included in the review 
(e.g., study risk of bias, inconsistency and imprecision). 
Interpretation 10 Provide a general interpretation of the results and important implications. 
Other 
Funding 11 Specify the primary source of funding for the review. 
Registration 12 Provide the register name and registration number. 
∗ This abstract checklist retains the same items as those included in the PRISMA for Abstracts statement published in 2013 [54] , but has 
been revised to make the wording consistent with the PRISMA 2020 statement and includes a new item recommending authors specify the 
methods used to present and synthesise results (item #6). 
PRISMA statement [35] , discussed the findings at an 
in-person meeting, and prepared this document through 
an iterative process. Our recommendations are informed 
by the reviews and survey conducted before the in-person 
meeting, theoretical considerations about which items 
facilitate replication and help users assess the risk of bias 
and applicability of systematic reviews, and coauthors’ 
experience with authoring and using systematic reviews. 
Various strategies to increase the use of reporting 
guidelines and improve reporting have been proposed. 
They include educators introducing reporting guidelines 
into graduate curricula to promote good reporting habits 
of early career scientists [65] ; journal editors and reg- 
ulators endorsing use of reporting guidelines [18] ; peer 
reviewers evaluating adherence to reporting guidelines 
[61 , 66] ; journals requiring authors to indicate where in 
their manuscript they have adhered to each reporting item 
[67] ; and authors using online writing tools that prompt 
complete reporting at the writing stage [60] . Multipronged 
interventions, where more than one of these strategies is 
combined, may be more effective (such as completion of 
checklists coupled with editorial checks) [68] . However, of 
31 interventions proposed to increase adherence to report- 
ing guidelines, the effects of only 11 have been evaluated, 
mostly in observational studies at high risk of bias due to 
confounding [69] . It is therefore unclear which strategies 
should be used. Future research might explore barriers and 
facilitators to the use of PRISMA 2020 by authors, editors, 
and peer reviewers, designing interventions that address 
the identified barriers, and evaluating those interventions 
using randomized trials. To inform possible revisions to 
the guideline, it would also be valuable to conduct think- 
aloud studies [70] to understand how systematic reviewers 
interpret the items, and reliability studies to identify items 
where there is varied interpretation of the items. 
We encourage readers to submit evidence that informs 
any of the recommendations in PRISMA 2020 (via the 
PRISMA statement website: http://www.prisma-statement. 
org/). To enhance accessibility of PRISMA 2020, several 
translations of the guideline are under way (see available 
translations at the PRISMA statement website). We en- 
courage journal editors and publishers to raise awareness 
of PRISMA 2020 (for example, by referring to it in 
journal “Instructions to authors”), endorsing its use, advis- 
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Fig. 1. PRISMA 2020 flow diagram template for systematic reviews. The new design is adapted from flow diagrams proposed by Boers [55] , 
Mayo-Wilson et al. [56] and Stovold et al. [57] . The boxes in gray should only be completed if applicable; otherwise they should be removed 
from the flow diagram. Note that a “report” could be a journal article, preprint, conference abstract, study register entry, clinical study report, 
dissertation, unpublished manuscript, government report or any other document providing relevant information. 
ing editors and peer reviewers to evaluate submitted sys- 
tematic reviews against the PRISMA 2020 checklists, and 
making changes to journal policies to accommodate the 
new reporting recommendations. We recommend existing 
PRISMA extensions [47 , 49–53 , 71 , 72] be updated to reflect 
PRISMA 2020 and advise developers of new PRISMA 
extensions to use PRISMA 2020 as the foundation 
document. 
6. Conclusion 
We anticipate that the PRISMA 2020 statement will 
benefit authors, editors, and peer reviewers of systematic 
reviews, and different users of reviews, including guideline 
developers, policy makers, healthcare providers, patients, 
and other stakeholders. Ultimately, we hope that uptake of 
the guideline will lead to more transparent, complete, and 
accurate reporting of systematic reviews, thus facilitating 
evidence based decision making. 
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